Ken Griffin Axogen, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$7.52 - $14.69 $108,288 - $211,536	-14,400 Reduced 35.91%	25,700 $360,000
Q2 2024 Aug 14, 2024	SELL	$5.67 - $8.06 $3,402 - $4,836	-600 Reduced 1.47%	40,100 $290,000
Q1 2024 May 15, 2024	BUY	$6.63 - $10.69 $255,918 - $412,634	38,600 Added 1838.1%	40,700 $328,000
Q4 2023 Feb 14, 2024	SELL	$3.61 - $7.76 $72,561 - $155,976	-20,100 Reduced 90.54%	2,100 $14,000
Q3 2023 Nov 14, 2023	SELL	$4.68 - $9.26 $261,143 - $516,708	-55,800 Reduced 71.54%	22,200 $111,000
Q2 2023 Aug 14, 2023	SELL	$8.5 - $10.38 $321,300 - $392,364	-37,800 Reduced 32.64%	78,000 $712,000
Q1 2023 May 15, 2023	BUY	$7.53 - $10.95 $431,469 - $627,435	57,300 Added 97.95%	115,800 $1.09 Million
Q4 2022 Feb 14, 2023	BUY	$9.44 - $13.09 $225,616 - $312,851	23,900 Added 69.08%	58,500 $583,000
Q3 2022 Nov 14, 2022	SELL	$8.14 - $12.25 $429,792 - $646,800	-52,800 Reduced 60.41%	34,600 $412,000

163

36.6M

230K

400

Ticker AXGN
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 42,283,700
Market Cap $564M
Description
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.